New drug aims to control advanced cervical cancer

NCT ID NCT05475171

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorigerlimab (MGD019), a drug given by IV
What this could lead to: If it works, this could offer a new treatment option to help control advanced cervical cancer and improve survival.
What could go wrong: This is a small, early-phase trial that is currently suspended. It may not show benefit, and immunotherapy can cause side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer metastatic malignant neoplasm Neoplasm Metastasis Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER METASTATIC CANCER

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.